VLX
(2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide
| Created: | 2023-07-28 |
| Last modified: | 2024-05-01 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 35 |
| Chiral Atom Count | 2 |
| Bond Count | 35 |
| Aromatic Bond Count | 0 |
Chemical Component Summary | |
|---|---|
| Name | (2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide |
| Systematic Name (OpenEye OEToolkits) | (2~{S})-2-[(4~{R})-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide |
| Formula | C11 H20 N2 O2 |
| Molecular Weight | 212.289 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | CACTVS | 3.385 | CCC[CH]1CN([CH](CC)C(N)=O)C(=O)C1 |
| SMILES | OpenEye OEToolkits | 2.0.7 | CCCC1CC(=O)N(C1)C(CC)C(=O)N |
| Canonical SMILES | CACTVS | 3.385 | CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 |
| Canonical SMILES | OpenEye OEToolkits | 2.0.7 | CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N |
| InChI | InChI | 1.06 | InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1 |
| InChIKey | InChI | 1.06 | MSYKRHVOOPPJKU-BDAKNGLRSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB05541 |
|---|---|
| Name | Brivaracetam |
| Groups |
|
| Description | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760]. |
| Synonyms | Brivaracetam |
| Brand Names |
|
| Indication | Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older. |
| Categories |
|
| ATC-Code | N03AX23 |
| CAS number | 357336-20-0 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| Synaptic vesicle glycoprotein 2A | MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFE... | unknown | unknown |
| Sodium channel protein | MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPK... | unknown | inhibitor |
| Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | substrate |
| Cytochrome P450 2C19 | MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV... | unknown | substrate |
| Cytochrome P450 2B6 | MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG... | unknown | substrate |
| View More | |||
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL607400 |
| PubChem | 9837243 |
| ChEMBL | CHEMBL607400 |
| ChEBI | CHEBI:133013 |
| CCDC/CSD | NASROP01, NASROP, ZIKFOR |














